Lennox Gastaut Syndrome

LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show.

Caregivers for those with Lennox Gastaut and Dravet syndrome reported that cannabidiol treatment led to improved nonseizure outcomes and reduced seizure burden, according to a study from Epilepsy Research.

Clinical outcome assessments currently used for people with Lennox-Gastaut syndrome and Dravet syndrome were “not fit” for evaluating non-seizure outcomes, researchers said, prompting the development of a global clinical impression measure.

NeuroPace Inc. announced that the first patient with Lennox-Gastaut Syndrome was treated in its investigational device exemption feasibility study, which will evaluate the company’s neuromodulation technology.

Patients with Lennox-Gastaut syndrome experienced a significant reduction in drop seizures with fenfluramine, according to results of a clinical trial published in JAMA Neurology.

Pediatric patients with epilepsy treated with pharmaceutical CBD had better seizure control than those treated with artisanal CBD, according to findings from a retrospective chart review that will be presented at the American Academy of Neurology annual meeting this spring.